| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, Mass.—XtalPi Inc., a computation-driven biotech startup integrating quantum physics, artificial intelligence (AI) and cloud computing to empower pharmaceutical research, recently announced a Series B-1 extension financing of $46 million to support its continuous market growth and expand the application of its technology into new areas of pharmaceutical research.
 
Building on XtalPi’s current momentum and success, the new financing will fuel the development of AI applications for critical steps of drug research and development, with an immediate focus on algorithmic tools that expand the searchable chemical space in drug discovery, achieve accurate predictions of key drug properties and help further accelerate and optimize later stages of drug development. In addition, XtalPi is poised to upgrade its Intelligent Digital Drug Discovery and Development (ID4) platform with industry-leading cloud computing power and data security in order to offer highly customized solutions to meet the particular needs of pharmaceutical companies.
 
“XtalPi has gained approval and endorsement from pharmaceutical clients as we continue to help them cut cost, time and risk in pharmaceutical research,” said Shuhao Wen, co-founder and chairman of the board at XtalPi. “For the next step, we want to open our base solution platform to support other developers of drug research and development algorithms. Through this, we will help global pharmaceutical companies connect with a wide range of the latest AI research tools in an easily accessible way, and thereby further improve the efficiency of drug discovery and development.”

Related Topics

Published In

Volume 15 - Issue 2 | February 2019

February 2019

February 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue